IP portfolio composition (approximate): Composition-of-matter patents: expired 2016 (US) and 2018 (EU) Manufacturing process patents: extended effective protection through 2022 and beyond in some jurisdictions Formulation patents: citrate-free high-concentration formulation, enabling the Humira CF transition Device patents: proprietary auto-injector design Method-of-use patents: spanning 14 approved indications including RA, Crohns disease, psoriasis, uveitis, and pediatric extensions IP valuation framework: At peak, Humiras patent portfolio represented approximately $15-18 billion in net present value of protected cash flows (using a 10% discount rate, a 75% probability of litigation success based on historical BPCIA outcomes, and a 3-year median delay from patent challenge to market entry)
This precision approach aligns with personalized treatment planning rather than assumptions based on average outcomes
You can have your provider send us a prescription, or connect with our trusted telemedicine partner
GLP medications mimic this hormones powerful effects--helping you feel full faster, stay satisfied longer, and lower blood sugar levels more effectively
For example, in a 68-week clinical trial, semaglutide users experienced an average weight loss of 15.8%, with 86% of participants achieving clinically meaningful results
